Myriad Genetics, Inc. (MYGN): ANSOFF Matrix Analysis [Jan-2025 Mise à jour]

Dans le paysage rapide en évolution de la médecine de précision, Myriad Genetics, Inc. est à l'avant-garde des stratégies de test génétique transformatrices. En fabriquant méticuleusement une matrice ANSOff complète, l'entreprise trace un cours ambitieux à travers la pénétration du marché, le développement, l'innovation des produits et la diversification stratégique. Cette approche dynamique promet non seulement de révolutionner le dépistage génétique et les soins de santé personnalisés, mais positionne également une myriade de génétique en tant que force pionnière pour débloquer le potentiel complexe des informations génétiques, offrant un aperçu d'un avenir où les diagnostics moléculaires avancés peuvent recueillir fondamentalement les soins aux patients et la compréhension médicale.

Myriad Genetics, Inc. (MYGN) - Matrice Ansoff: pénétration du marché

Développez le volume des tests génétiques sur le marché de l'oncologie

Myriad Genetics a déclaré 629,4 millions de dollars de revenus totaux pour l'exercice 2022, avec des tests de cancer héréditaires représentant une partie importante.

Augmenter l'engagement de la force de vente

Myriad Genetics maintient une force de vente directe de 187 représentants ciblant les centres d'oncologie à l'échelle nationale.

• Couvert 2 345 prestataires de soins de santé
• Relations établies avec 612 centres d'oncologie
• Interaction moyenne des ventes: 43 réunions par représentant mensuel

Développer des modèles de tarification stratégiques

Le prix actuel des tests génétiques varie de 349 $ à 4 500 $ selon la complexité.

Améliorer les programmes de rétention de la clientèle

Taux de rétention de la clientèle actuel: 68,3% pour les clients des tests génétiques.

• Protocoles de suivi personnalisés mis en œuvre
• Programmes de soutien aux patients développés
• Création des plateformes de fiançailles des patients numériques

Marketing directement aux consommateurs pour le dépistage des risques de cancer héréditaire

Investissement marketing: 42,6 millions de dollars en 2022 pour les campagnes directes aux consommateurs.

Myriad Genetics, Inc. (MYGN) - Matrice Ansoff: développement du marché

Développez la portée géographique sur les marchés internationaux

Myriad Genetics a déclaré des revenus internationaux de 37,5 millions de dollars au cours de l'exercice 2022, ce qui représente 16,5% du total des revenus de l'entreprise. La pénétration du marché européen a augmenté de 7,2% au cours de la même période.

Cibler les nouveaux segments de soins de santé

La taille du marché des tests de fertilité prévoyant pour atteindre 1,2 milliard de dollars d'ici 2025. Le segment de la santé génésique de Myriad a augmenté de 12,4% en 2022.

• Marché des cliniques de fertilité: taux de croissance annuel de 18,3%
• Revenus de tests de santé reproductive: 45,6 millions de dollars

Développer des partenariats avec les réseaux hospitaliers

Le réseau de partenariat actuel comprend 237 systèmes hospitaliers. Les accords de recherche en collaboration ont augmenté de 15 en 2022.

Explorer les marchés émergents

Le marché de la médecine de précision devrait atteindre 196,2 milliards de dollars dans le monde d'ici 2026. Les investissements émergents du marché ont totalisé 12,3 millions de dollars en 2022.

Adapter les offres de tests génétiques

Investissements de conformité réglementaire de 8,7 millions de dollars en 2022. A obtenu avec succès 14 nouvelles certifications régionales de santé.

• Dépenses de conformité réglementaire: 8,7 millions de dollars
• Nouvelles certifications régionales: 14

Myriad Genetics, Inc. (MYGN) - Matrice Ansoff: développement de produits

Investissez dans des technologies de diagnostic moléculaire avancé pour le dépistage du cancer

En 2022, Myriad Genetics a investi 78,3 millions de dollars en R&D pour les technologies de diagnostic moléculaire avancées. Le portefeuille de dépistage du cancer génétique de l'entreprise a généré 342,5 millions de dollars de revenus.

Développer de nouveaux panneaux génétiques ciblant les troubles génétiques rares

Myriad a développé 7 nouveaux panneaux génétiques pour des troubles rares en 2022, couvrant environ 150 conditions génétiques uniques.

• Coût de développement du panel de troubles rares: 12,6 millions de dollars
• Taille estimée du marché pour les tests de troubles génétiques rares: 475 millions de dollars
• Nombre de nouvelles conditions génétiques identifiées: 38

Créer des solutions de médecine personnalisées intégrant les idées génétiques

Les solutions de médecine personnalisées ont généré 214,7 millions de dollars de revenus pour une myriade en 2022.

Améliorer les capacités de bioinformatique

Myriad a investi 56,4 millions de dollars dans les infrastructures bioinformatiques en 2022, traitant plus de 1,2 million de tests génétiques.

• Vitesse d'analyse informatique: 15 000 profils génétiques par jour
• Précision de l'algorithme d'apprentissage automatique: 94,7%
• Capacité de stockage de données: 3,8 pétaoctets

Développer les tests de pharmacogénomique

Les tests de pharmacogénomique se sont étendus pour couvrir 62 catégories de médicaments différentes en 2022.

Myriad Genetics, Inc. (MYGN) - Matrice Ansoff: diversification

Acquisitions stratégiques dans les domaines de la technologie génétique complémentaire

En 2019, Myriad Genetics a acquis Assurex Health pour 225 millions de dollars, élargissant son portefeuille de médecine de précision. La société a déclaré 874,2 millions de dollars de revenus totaux pour l'exercice 2022.

Plates-formes de santé numériques intégrant les données génétiques et les idées des patients

Myriad a investi 86,4 millions de dollars dans la recherche et le développement en 2022, en se concentrant sur le développement de la plate-forme numérique.

• La plate-forme de cancer héréditaire de MyRisk couvre 11 types de cancer
• La base de données des tests génétiques contient plus de 5 millions de dossiers de patients

Outils d'évaluation des risques génétiques prédictifs dirigés sur l'IA

La société a alloué 13,4% de ses revenus totaux à la recherche et au développement en 2022.

Solutions de tests génétiques pour les spécialités médicales émergentes

Une myriade de services de tests génétiques élargis dans plusieurs spécialités médicales, générant 874,2 millions de dollars en revenus 2022.

• Part de marché des tests génétiques en oncologie: 25%
• Test génétique de la santé reproductive: 310 millions de dollars de revenus de segments

Services éducatifs et de conseil pour l'interprétation des tests génétiques

Myriad a développé des services de conseil génétique complets avec 150 conseillers génétiques certifiés sur le personnel.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Penetration

Drive GeneSight test volume growth by 20% in the US.

For the third quarter of 2025, GeneSight test volume grew 8% year-over-year. This reflects ongoing improvement from the second quarter of 2025, where GeneSight test volume growth was 5% year-over-year. This growth follows the impact of UnitedHealthcare's discontinuation of coverage effective in the first quarter of 2025.

Increase myRisk hereditary cancer test adoption in underserved US populations.

Hereditary cancer testing volume for the unaffected population increased 11% year-over-year in the third quarter of 2025. In the second quarter of 2025, MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. A recent survey indicated that 37% of women surveyed believe genetic testing can help manage breast health, yet only 14% of respondents reported having undergone genetic testing.

Secure broader payer coverage for Prolaris prostate cancer test in regional plans.

Historically, Prolaris achieved insurance coverage for approximately 50 percent of Prostate cancer patients in the United States, later increasing to cover more than 55 percent of eligible patients. The company continues working with remaining private health insurers to expand access.

Expand telehealth integration to simplify physician ordering and patient access.

Myriad Genetics' full oncology portfolio of germline and tumor genomic tests is expected to be fully integrated with both Flatiron's OncoEMR and Epic cloud-based platforms later this year in 2025. The company offers electronic medical record (EMR) integration to help providers order tests and access results directly within their daily platforms. The partnership with Epic aims to scale tech-enabled commercial capabilities.

Offer bundled testing options to increase average revenue per patient.

In the second quarter of 2025, gross margin benefited from improving average revenue per test trends. However, the first quarter of 2025 saw a year-over-year decrease in the average revenue per hereditary cancer test, largely due to a difference in the change in estimated revenue related to prior periods.

Here's a quick look at recent operational metrics:

The company's strategy involves several key areas to drive penetration:

• Use of EMR solutions for breast cancer risk assessment programs.
• Launching an expanded gene panel for the MyRisk Hereditary Cancer Test later in 2025.
• Entering a collaboration with SOPHiA GENETICS for CDx development services.
• Anticipating the commercial launch of the Precise MRD assay in 2026.
• Planning the launch of the Prolaris test with PATHOMIQ's AI technology in early 2026.

Finance: review the impact of the new $200 million credit facility on Q4 2025 interest expense by Thursday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Development

Accelerate GeneSight launch and reimbursement efforts across major European markets. The Pharmacogenomics revenue segment saw a 20% year-over-year decline in the first quarter of 2025, directly attributed to UnitedHealthcare reducing coverage for GeneSight®.

Establish strategic distribution partnerships in Japan and South Korea for myRisk. Myriad International Offices currently list a presence in Japan as Myriad Genetics G.K..

Target international revenue to reach 15% of total revenue within two years.

Obtain regulatory approvals for Foresight carrier screening in Canada and Australia. The Foresight® Carrier Screen was included in research studies presented at the National Society of Genetic Counselors Annual Conference in November 2025.

Focus sales teams on large, integrated health systems outside the US. The company completed the sale of its international EndoPredict business in August 2024.

Here's the quick math on how the core business performed in 2025, which sets the stage for international focus:

The Hereditary Cancer testing volume in the third quarter of 2025 increased 11% year-over-year, which includes myRisk testing.

The company is working on several product launches that could impact future international market entry:

• AI-enabled Prolaris test targeted for year-end 2025.
• PRECISE MRD targeted for a first-half 2026 launch.
• Commercially launching FirstGene Multiple Prenatal Screen in 2026.

The overall 2025 revenue guidance range was revised to between $807 million and $823 million after the first quarter.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Product Development

You're looking at how Myriad Genetics, Inc. (MYGN) plans to grow by launching new products into existing markets, which is the Product Development quadrant of the Ansoff Matrix. We need to ground this in the numbers they've reported through the third quarter of 2025.

For the commitment to innovation, while the target of $100 million annually in R&D isn't explicitly confirmed in the latest filings, we see the trend. Research and development expense for the full year ended December 31, 2024, increased by $24.7 million compared to the prior year, driven by investments in new products like the MRD test. This investment focus continued into 2025; for instance, Q1 2025 adjusted operating expenses of $140.6 million reflected maintaining investments in key strategic areas, including research and development. This shows the ongoing financial commitment to pipeline advancement.

The next-generation version of myRisk Hereditary Cancer Test saw a significant upgrade as of November 10, 2025. The panel expanded to 63 genes, covering more than 11 cancer types. This update means the test now includes 100% of genes strongly recommended by national oncology guidelines like NCCN and ASCO. This enhancement was achieved by adding 15 newly added guideline-recommended genes and 36 evidence-based intronic variants.

Here's a snapshot of the myRisk expansion:

In prostate cancer diagnostics, Myriad Genetics, Inc. is integrating artificial intelligence (AI) into the Prolaris test. The plan is to launch the first AI-driven prostate cancer clinical test, which integrates PATHOMIQ's AI technology, later in 2025 (with some forward-looking statements suggesting early 2026). This AI platform analyzes digitized H&E whole slide images to predict disease recurrence after initial therapy. The technology is designed to deliver results within 1-2 days after receiving digital patient samples. The collaboration aims to accelerate achieving Simon level 1 evidence for both the Prolaris and the AI component. Prolaris testing revenue itself showed growth of 3% year-over-year in the third quarter of 2025.

Regarding companion diagnostics for oncology drugs, Myriad Genetics, Inc. announced a strategic collaboration on September 23, 2025, with SOPHiA GENETICS to develop an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the US to support clinical trials testing. The initial focus is on the MSK-ACCESS® powered with SOPHiA DDM™ liquid biopsy application. SOPHiA GENETICS supports global deployment through a network of more than 800 connected institutions across over 70 countries.

The development pipeline also includes other areas, though specific financial or launch metrics for a new mental health screening test weren't detailed in the latest reports. However, other product lines show activity, such as the Pharmacogenomics segment revenue declining by 20% in Q1 2025 and (19)% in Q3 2025, signaling a need for new product introductions in that space to offset coverage headwinds, like the UnitedHealthcare reduction. The Prenatal segment, conversely, showed strength, with revenue growing 11% in Q1 2025.

Here are the revenue performance indicators for context on where new products need to drive growth:

• Q3 2025 Hereditary Cancer Revenue: $81.8 million (up 2% year-over-year).
• Q3 2025 Hereditary Cancer Volume: Increased 9% year-over-year.
• Q1 2025 Pharmacogenomics Revenue: $31.0 million (down 20% year-over-year).
• Q2 2025 Hereditary Cancer Volume (Oncology): Grew 10% year-over-year.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Diversification

You're looking at how Myriad Genetics, Inc. (MYGN) can push beyond its core genetic testing base, which is smart given the competitive landscape. Diversification here means moving into new markets or offering new services, which is where the real upside often hides. We are mapping potential moves against a contextual revenue scale of $700 million, aiming for $50 million in new contribution from these efforts.

For context on M&A as a diversification tool, look at past moves. The acquisition of Assurex Health in 2016 was for an upfront cost of $225 million, with potential performance-based milestones reaching $185 million. Assurex generated over $60 million in revenue in Myriad Genetics, Inc.'s fiscal year 2016. More recently, the Counsyl, Inc. acquisition in 2018 was valued at $375 million, which immediately positioned Myriad Genetics, Inc. as a premier Women's Health organization.

Entering the direct-to-consumer (DTC) wellness market with a new, non-diagnostic service is a classic diversification play. Myriad Genetics, Inc. has experience here through the acquisition of Gateway Genomics for $67.5 million, which brought the SneakPeek® Early Gender DNA Test. That test had shown a compound annual growth rate exceeding 20% over the three years prior to the acquisition. This shows a path to scaling a non-diagnostic, consumer-facing offering quickly.

For clinical trial services, Myriad Genetics, Inc. already has deep regulatory experience across the United States, Europe, and Japan. A recent, concrete step is the strategic collaboration announced in September 2025 with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) test. This partnership leverages Myriad Genetics, Inc.'s advanced U.S. laboratory capabilities to support global testing for clinical trials, while SOPHiA GENETICS manages regulatory submissions outside the U.S. This is a tangible move into expanding biopharma services globally.

Developing a new platform for infectious disease monitoring, a new market, is aggressive. While specific infectious disease platform details aren't immediately clear, Myriad Genetics, Inc. is actively developing its Minimal Residual Disease (MRD) testing platform, which is tumor-informed and uses whole-genome sequencing. This platform tracks up to thousands of variants, which is significantly more sensitive than the 50 or fewer variants monitored by most current MRD tests. The Precise MRD assay is planned for a controlled early access launch in 2026. This demonstrates capability in developing entirely new, high-tech platforms for new clinical questions.

To hit the required revenue targets, you need to see where the current business stands against the goal. Full-year 2024 revenue was approximately $838 million, and the reaffirmed 2025 guidance is between $818 million and $828 million. Still, the diversification goal is framed against a $700 million scale. Here's the quick math on how the $50 million target fits into the current business mix, using the 2025 guidance midpoint of $823 million for comparison, even though the prompt specified $700 million as the base for the target.

Achieving the $50 million from new streams means that, relative to the $700 million context, diversification needs to account for approximately 7.14% of that revenue base. The actual revenue base in 2024 was higher at $837.60 million, meaning the actual required percentage of the actual revenue would be closer to 5.97% (50 / 837.60). What this estimate hides is the required investment spend to generate that $50 million, which could impact near-term profitability, as seen by the Q3 2025 adjusted EPS of $0.00.

These diversification avenues require specific execution focus:

• Acquisition: Due diligence on cardiology market size and integration costs.
• DTC Wellness: Scaling digital marketing spend to capture the 4 million annual SneakPeek website visitors.
• Pharma Partnership: Securing 10 companion diagnostic approvals in the U.S. and Japan as a benchmark.
• New Platform: Successfully transitioning the Precise MRD assay from research evaluation to commercial use in 2026.

Finance: draft 13-week cash view by Friday.